Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Semaglutide in an Oral Microemulsion Study

A 2026 formulation paper used semaglutide as a model peptide, but its enzyme and animal findings are not evidence for oral treatment in people.

Why we wrote this. The abstract reports a relative oral-bioavailability result for an experimental carrier. We explain the comparator and keep it separate from approved oral semaglutide products.

In this article (5 sections)
  1. The delivery problem the paper targets
  2. What the experiments reported
  3. Why an animal pharmacokinetic result is not a prescription result
  4. The semaglutide label should not be transferred to this platform
  5. What would need to happen next

A 2026 laboratory paper describes an oil-protected microemulsion designed to help ionic-liquid formulations remain intact in simulated gastrointestinal conditions. The researchers used paclitaxel and semaglutide as model drugs. In the indexed abstract, the semaglutide result concerns enzyme-exposure tests and animal pharmacokinetics, not oral semaglutide treatment in people.[1] That distinction is the starting point for reading the work.

Semaglutide is already used in authorised prescription products, including an oral tablet in some markets. This paper does not test an authorised tablet, compare itself with a marketed product, or provide a new dose for patients. For product context, see our semaglutide overview and semaglutide safety section.

The delivery problem the paper targets

Peptide medicines face several barriers after oral administration. The abstract describes low solubility, poor permeability and enzymatic degradation in the gastrointestinal tract as obstacles to oral delivery of peptide therapeutics.[1] An ionic liquid can alter solubility and stability, but the authors say rapid dilution and ion-pair dissociation in an aqueous gastrointestinal environment can reduce the formulation's performance.

The proposed answer was a self-emulsifying ionic-liquid microemulsion, called IL-ME. The platform combined choline geranate ionic liquid, medium-chain triglycerides as an oil phase and surfactants. The idea was to slow dilution by surrounding the ionic-liquid phase with an oil-containing system while it moved through gastrointestinal fluids.

What the experiments reported

For paclitaxel, the abstract reports that more than 70% of loaded drug remained dissolved after incubation in simulated gastrointestinal fluids in IL-ME formulations, compared with less than 50% in plain ionic liquid.[1] That is a formulation stability observation for a small-molecule model drug. It does not by itself establish absorption or clinical benefit for semaglutide.

For semaglutide, the abstract reports resistance to trypsin digestion and maintenance of stability against pepsin degradation for 90 minutes in the described experiments.[1] These are controlled laboratory conditions. Digestion, mucus, motility, food effects, intestinal transport and first-pass processes can change how a formulation behaves in a living system.

The authors also report pharmacokinetic studies in which the IL-ME increased semaglutide oral bioavailability by 2.89-fold relative to plain ionic-liquid formulations.[1] The comparison is important. It is against plain ionic liquid, not against an approved oral semaglutide product, an injection or placebo. The indexed abstract does not identify a human participant group.

Why an animal pharmacokinetic result is not a prescription result

Bioavailability describes how much administered drug reaches systemic circulation. A relative improvement can be scientifically useful while still leaving open the absolute exposure, variability, dose, safety margin and manufacturability needed for a medicine. Those questions cannot be answered from a relative figure alone.

The abstract reports prolonged gastrointestinal retention using a fluorescence probe and says safety evaluation found no significant toxicity or intestinal inflammation after repeated oral dosing. Those are findings within the reported preclinical program. They do not establish human tolerability, long-term safety, drug interactions or the performance of a retail formulation.

The reported experiments answer narrower questions than a clinical program. They ask whether the carrier protected cargo under simulated digestive conditions and whether exposure changed in the study model. They do not tell us how often an effect would occur across patients, whether food would change it, or whether the carrier ingredients would be acceptable at a therapeutic scale. Those are separate development questions.

The semaglutide label should not be transferred to this platform

FDA labeling for Rybelsus describes a specific oral semaglutide product and formulation. The label is evidence for that approved product, not for experimental ionic-liquid microemulsions.[2] The paper's IL-ME combines different ingredients and was evaluated as a laboratory delivery system.

This separation protects against a common mistake in early delivery research: assuming an established active ingredient makes a new carrier clinically established. The active ingredient, delivery vehicle, exposure profile and manufacturing controls all matter. A result for a custom platform belongs to that platform until direct evidence supports a narrower conclusion.

What would need to happen next

Before an experimental oral delivery system could inform routine care, researchers would need to establish reproducible manufacture, stability, absolute exposure, dose-response behavior, toxicology and comparative performance. Human clinical trials would then need to assess pharmacokinetics, adverse events and outcomes for the defined formulation. Each stage can change or contradict an earlier laboratory result.

The paper is therefore best read as formulation research. It presents a mechanism for protecting an ionic-liquid system from dilution and reports encouraging preclinical findings using semaglutide as a model peptide. It does not show that patients can make, obtain or substitute an IL-ME product, and it does not support changing prescribed semaglutide treatment.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

Did this paper test oral semaglutide in people?

No. The accessible indexed abstract describes laboratory testing and preclinical pharmacokinetic work, not a human trial.

What was the comparison for the 2.89-fold result?

The abstract reports comparison with a plain ionic-liquid formulation, not an approved oral semaglutide product or placebo.

Does the study validate an oral semaglutide product?

No. It tested an experimental ionic-liquid microemulsion with a different delivery system.

Can this research guide a dose or product substitution?

No. The paper does not provide evidence for patient dosing or substituting a prescribed medicine.

Sources

  1. [1]NCBI PubMed EFetch: An oil-protected microemulsion strategy overcomes ionic liquids instability in the gastrointestinal tract for enhanced oral drug delivery. PMID 43039120.Tier 1 · primary↩
  2. [2]DailyMed: Rybelsus (oral semaglutide) tablets prescribing informationTier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars